A Phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

PURPOSE: Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of AR-42 in patients with advanced solid tumors, including neurofibromatosis type 2 asso...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Collier, Katharine A., Valencia, Hugo, Newton, Herbert, Hade, Erinn M., Sborov, Douglas W., Cavaliere, Robert, Poi, Ming, Phelps, Mitch A., Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Khountham, Soun, Monk, Paul, Shapiro, Charles L., Piekarz, Richard, Hofmeister, Craig C., Bradley Welling, D., Mortazavi, Amir
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8162746/
https://ncbi.nlm.nih.gov/pubmed/33492438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04229-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados